Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dengvaxia + Pentaxim
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Dengvaxia + Pentaxim refers to the concomitant administration of Sanofi Pasteur's tetravalent dengue vaccine (CYD-TDV, Dengvaxia) and the pentavalent vaccine Pentaxim (DTaP-IPV/Hib). Dengvaxia is a live-attenuated, recombinant vaccine that utilizes a yellow fever 17D virus backbone to express the pre-membrane and envelope proteins of the four dengue virus serotypes (DENV-1, -2, -3, and -4). Pentaxim is a combined vaccine designed to protect against diphtheria, tetanus, pertussis (acellular), poliomyelitis (inactivated), and invasive infections caused by Haemophilus influenzae type b. This specific combination regimen was evaluated in Phase 3 clinical trials (such as NCT01204632) to assess the safety and immunogenicity of administering a Pentaxim booster dose simultaneously with the second dose of the dengue vaccine in healthy toddlers aged 15-18 months. The study aimed to ensure that co-administration does not interfere with the protective immune response generated by either vaccine component.
- Brand names
- DengvaxiaPentaxim
- Other names
- regorafenib + TAS-102-Sanofi Pasteur, a Sanofi Company-dengueCYD dengue vaccine + Pentaxim
02
Targets
DENV-4 E (Dengue virus serotype 4 envelope protein)TT (Tetanus toxoid)DENV-1 E (Dengue virus serotype 1 envelope protein)DENV-2 E (Dengue virus serotype 2 envelope protein)Diphtheria toxinDENV-3 E (Dengue virus serotype 3 envelope protein)prM (Zika virus precursor membrane protein)
Beyond the preview
Go deeper on Dengvaxia + Pentaxim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dengvaxia + Pentaxim.